The document discusses strategies for pharmaceutical companies to move beyond just selling pills to developing value-added services. It recommends that companies first undertake mapping to determine the optimal breadth and customization level of services, which can be categorized into archetypes. A rigorous review is then needed to identify what services to provide internally versus using external partners. While services have traditionally been free, new commercial models may be needed to sustain comprehensive service strategies and maximize value for stakeholders.